Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 8/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4831418 | 0.90 | PGR (0.45) | PGRCYP3A4CYP2D6PPARGFFAR1 | |
| SCHEMBL4834490 | 0.89 | CYP3A4 (0.46) | PGRCYP3A4PSEN1PSEN2APH1B | |
| SCHEMBL4836849 | 0.88 | PGR (0.37) | PGRCYP3A4CYP2D6FFAR1FFAR4 | |
| SCHEMBL4829094 | 0.87 | PGR (0.46) | PGRMAPTNPSR1 | |
| SCHEMBL4831477 | 0.85 | ALDH1A1 (0.48) | PGRMAPTKMT2A | |
| SCHEMBL4829026 | 0.83 | MAPT (0.48) | PGRCYP3A4CYP2D6MAPTNPSR1 | |
| SCHEMBL4836622 | 0.83 | MEN1 (0.42) | MAPTNPSR1KMT2A | |
| SCHEMBL4836678 | 0.83 | TP53 (0.46) | FFAR4MAPT | |
| SCHEMBL4833207 | 0.83 | LMNA (0.40) | PGRFFAR1FFAR4MAPTKMT2A | |
| SCHEMBL4834407 | 0.83 | PGR (0.46) | PGRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | claimed |
| US-20050004142-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | claimed |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | disclosed |
| US-7427623-B2 | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-23 | — | — | US | disclosed |
| US-20050004142-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | disclosed |
| EP-1425284-A2 | FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003022852-A2 | FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004142-A1 | Chemical compounds | TIE1, KDR, TEK | PGR 1159/4885CYP3A4 2352/4885PSEN1 2600/4885 |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TIE1, TEK, KDR | PGR 1480/4885CYP3A4 1914/4885PSEN1 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.